Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#1102 First-Line Chemotherapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): A Retrospective Analysis

Introduction: Gastroenteropancreatic neuroendocrine neoplasia (GEP-NENs) are divided on the basis of Ki67 status into G1-G2 neuroendocrine tumors (NETs) (Ki67 <20%) and neuroendocrine carcinoma (NECs) (Ki67 >20% ). NEC patients generally have a poor prognosis and the first choice treatment is chemotherapy.A cisplatin/etoposide combination is often used as NECs are considered clinically similar to small cell lung cancer (SCLC), but no literature data is available. There is some evidence to suggest that carboplatin may also be effective in metastatic SCLC.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: IBRAHIM T

Authors: Bongiovanni A, Riva N, Monti M, Ianniello A, Pieri F,

Keywords: GEP-NEC,chemotherapy,

#695 Pancreatic Angiography with Selective Intra-Arterial Calcium Stimulation for the Localization of Insulinomas: A Case Report.

Introduction: Surgery is the gold standard treatment of insulinomas. Before planning the surgical procedure, the tumor must be precisely localized. Usually, the combination of Endoscopic Ultrasound, Computed Tomography and Magnetic Resonance Imaging localize more than 80% of the tumors. But due to its small size, other more sophisticated techniques must be performed in order to improve the diagnosis accuracy. Some of them, like angiography, are invasive.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Pi J

Authors: Chu-Montiel D, De La Maza L, Pi J, Aldea J, Sánchez-Manuel J,

Keywords: insulinoma, pancreatic angiography, intra-arterial calcium stimulation,

#411 Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Introduction: Peptide receptor radionuclide therapy with 177Lu-DOTATATE (177Lu-PRRT) has shown activity against advanced well-differentiated pancreatic neuroendocrine tumors (P-NET) in previous phase I/II studies.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O,

Keywords: neuroendocrine, peptide receptor radionuclide therapy,